
Brain Swelling (Cerebral Edema): What You Need to Know
Fortunately medical teams have established evidence based ways to manage brain edema, reduce intracranial pressure (ICP) and give the brain the best chance to heal. The body's response to brain injury or illness often leads to swelling and increased intracranial pressure so prompt intervention is critical.
The first step in medically managing brain edema is often a type of treatment called hyperosmolar therapy. This is also known as osmotic therapy which uses agents to create an osmotic gradient and manage cerebral edema. The 2022 AHA/ASA guidelines highlight this as the primary approach especially for swelling related to a brain bleed [1].
The two main workhorses of this therapy are:
These medications work through osmosis. They make your blood slightly 'thicker' or more concentrated than the fluid in your brain cells. This concentration difference creates an osmotic gradient which naturally pulls the excess water out of the swollen brain tissue and into the bloodstream. From there your body can process and eliminate the fluid, reducing the swelling and the pressure inside the skull. These interventions are designed to decrease cerebral edema by removing excess water from the brain.
Mannitol is one of the most common and effective agents to treat brain swelling. According to its FDA drug label, its primary job is to increase the osmolality (or concentration) of your blood plasma [3][4]. This is what pulls water out of the brain's intracellular space (inside the cells) into the extracellular fluid (the fluid outside the cells, including that in the blood vessels).
It's used for both adults and children but must be used carefully. Doctors will closely monitor a patient's ICP and other vital signs to make sure the dose is right for their situation.
Medication alone isn't enough. Brain edema management requires a multi-faceted approach where several simple yet critical interventions work together.
In some cases, the ICP continues to rise despite all medical efforts or there's an immediate threat of the brain shifting (a process called herniation) often due to intracranial hypertension. When this happens, surgical decompression may be the only way to save a patient's life.
The most common procedure is a decompressive craniectomy. During this surgery, a neurosurgeon temporarily removes a section of the skull. This creates an opening that gives the swollen brain room to expand without being compressed. A meta-analysis of studies showed that performing this surgery within 48 hours of a major stroke can reduce mortality and improve neurological outcomes [2].
Brain edema isn't a disease itself but a response to an underlying injury or illness, often resulting from acute brain injury. Common causes include head injury and head trauma which are common triggers of brain swelling. The most common triggers are:
Knowing the underlying cause and risk factors for brain edema is key to prognosis, treatment and patient outcomes. Doctors also classify edema based on how it forms. For example, vasogenic edema is caused by leaky blood vessels, while cytotoxic edema happens when the brain cells themselves swell. Cytotoxic and vasogenic edema can occur together, and other subtypes include ionic edema, which is water accumulation due to osmotic gradients, and interstitial edema, which is cerebrospinal fluid accumulation in the brain's extracellular space often due to hydrocephalus. These types of edema affect brain tissues leading to cellular swelling and if severe, cell death. Ischemic stroke and cerebral ischemia are major contributors to cytotoxic edema. Brain injuries of various types can disrupt normal brain function and structure and further exacerbate swelling and damage. Knowing the cause and type helps guide treatment.
Accurate diagnosis and monitoring is key to effective treatment. Critical care teams use:
Performing a neurological exam is crucial to assess for signs of elevated ICP, such as altered mental status or abnormal pupillary responses. These tools help detect and manage elevated ICP which is critical to prevent further brain injury.
Despite these tools, a 2025 international survey found that practices for monitoring and treating brain edema can vary significantly, so more standardized protocols are needed.
While current treatments work, researchers are always looking for better ones. Emerging therapies are targeting the molecular level, the ion channels, aquaporins (water channels) and inflammatory signals that cause fluid to accumulate in the first place . Recent advances highlight the importance of the blood-brain barrier and its endothelial cells in both the development and resolution of brain edema as their dysfunction can lead to increased vascular permeability and swelling.
A deeper understanding of the nervous system is driving new treatment strategies to improve outcomes. Hopefully these future treatments will be more precise and have fewer side effects. For more information on conditions of the brain, visit the World Health Organization's page on neurological disorders.
Brain edema is a tough medical problem but doctors are well equipped to handle it with a quick evidence-based approach. The foundation of treatment is hyperosmolar agents like mannitol but success depends on a comprehensive strategy that includes supportive care, close monitoring and when necessary, surgical intervention. Through the coordinated efforts of a multidisciplinary team of neurologists, neurosurgeons and critical care specialists, patients can get the individualized care they need to manage this condition.
[1] Rodgers, M. L., Fox, E., Abdelhak, T., Franker, L. M., Johnson, B. J., Kirchner-Sullivan, C., Livesay, S. L., Marden, F. A., & American Heart Association Council on Cardiovascular and Stroke Nursing and the Stroke Council (2021). Care of the Patient With Acute Ischemic Stroke (Endovascular/Intensive Care Unit-Postinterventional Therapy): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association. Stroke, 52(5), e198–e210. https://doi.org/10.1161/STR.0000000000000358
[2] Koenig M. A. (2018). Cerebral Edema and Elevated Intracranial Pressure. Continuum (Minneapolis, Minn.), 24(6), 1588–1602. https://doi.org/10.1212/CON.0000000000000665
[3] Liotta E. M. (2021). Management of Cerebral Edema, Brain Compression, and Intracranial Pressure. Continuum (Minneapolis, Minn.), 27(5), 1172–1200. https://doi.org/10.1212/CON.0000000000000988
[4] Halstead, M. R., & Geocadin, R. G. (2019). The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 16(4), 1133–1148. https://doi.org/10.1007/s13311-019-00779-4

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 hours ago
- Business Wire
Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device
LAKE FOREST, Calif.--(BUSINESS WIRE)--Single Pass Inc., a medical technology innovator focused on improving procedural safety in biopsy care, today announced the launch and first enrollment in B-S.A.F.E. (Biopsy with SinglePass: Assessing Fast & Effective Tract Closure) – a global, post-FDA market evaluation to generate real-world evidence of the SinglePass™ electrocautery biopsy closure device. I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver! This innovative device efficiently seals biopsy channels, reducing bleeding risks and improving patient safety across all my biopsy procedures. Share Despite the millions of solid organ percutaneous biopsies performed successfully each year, unintended bleeding post-procedure is a real risk requiring additional procedures, longer hospital stays, and increased costs. And in rare instances, the complications can be devastating. The SinglePass device is designed to cauterize the biopsy tract immediately after tissue extraction, offering a novel approach to reduce bleeding complications, enhance procedural efficiency, and optimize patient observation time. 'Single Pass's global post-market evaluation - B-S.A.F.E. - reflects our commitment to innovation backed by evidence,' said John Zehren, CEO of Single Pass Inc. 'We're honored to work alongside frontline clinicians to validate real-world safety, usability, and performance, bringing an innovative solution for patients undergoing biopsy procedures.' B-S.A.F.E. is a multicenter post-market device evaluation that will assess reduction in post-biopsy bleeding and complications, post-biopsy observation time and workflow optimization. 'The SinglePass device represents a transformational advancement in the world of core needle biopsy,' said Dr. Alexander Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital Irvine in Irvine, CA. 'With the ability of SinglePass to provide immediate and reliable tract closure, we are already witnessing an inevitable shift in the way we manage bleeding risk and patient recovery. I'm proud to contribute to this evaluation and help drive the future standard of care.' "I use SinglePass on every visceral biopsy for both tumor and parenchyma, including kidney and liver!' remarked Dr. Francis Kang, Clinical Chief of Interventional Radiology at Robert Wood Johnson University Hospital in New Brunswick, NJ. 'This innovative device efficiently seals biopsy channels, significantly reducing bleeding risks and improving patient safety across all my biopsy procedures." For more information, visit About Single Pass Inc. Single Pass Inc. is a privately held medical device company dedicated to enhancing safety and workflow efficiency in image-guided biopsy procedures. Its flagship device, the SinglePass Electrocautery Biopsy Closure Device, enables clinicians to cauterize the biopsy tract in a single step, potentially improving patient outcomes and reducing procedural complexity. The company is headquartered in Lake Forest, California.


Newsweek
3 hours ago
- Newsweek
Blueberry Recall Update as FDA Issues Most Severe Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of hundreds of boxes of blueberries due to possible contamination with Listeria monocytogenes has now been issued the highest risk warning by the U.S. Food and Drug Administration (FDA). Alma Pak International LLC, based in Georgia, issued a voluntary recall for 400 boxes of its organic blueberries on June 9. The FDA subsequently issued its Class 1 risk classification on July 1. Newsweek contacted Alma Pak International LLC for comment by email outside of regular working hours. Stock image. Alma Pak International LLC issued a voluntary recall for 400 boxes of its organic blueberries on June 9. Stock image. Alma Pak International LLC issued a voluntary recall for 400 boxes of its organic blueberries on June 9. Sina Schuldt/picture-alliance/dpa/AP Images Why It Matters A Class I risk classification represents "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death," according to the FDA. Listeria infection, or listeriosis, may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said. For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions. Severe infections are particularly dangerous for newborns, adults over age 65 and those with weakened immune systems. What To Know A total of 400 boxes of the firm's organic blueberries are impacted by the recall. Each box weighs 30 lbs. The blueberries were shipped to one customer in North Carolina, and can be identified by the Lot numbers: 13325 G1060 / 13325 G 1096. The recall was initiated after the firm obtained positive test results for Listeria monocytogenes during routine testing of the product. What People Are Saying Haley F. Oliver, a professor of food science at Purdue University, told Newsweek previously: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example in soil. There are many factors that determine if someone gets listeriosis — a listeria infection. In most instances, an immunocompromised person, so young, old, pregnant or otherwise immunocompromised, must eat contaminated food. The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance." Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, told Newsweek previously: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home, are a place where listeria can keep growing. "Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention." The FDA said on its website: "Pregnant women and their unborn or newborn baby, adults over the age of 65, and those with weakened immune systems, are all considered to be high-risk groups that are susceptible to the serious and adverse effects of listeriosis." What Happens Next The recall is listed as ongoing, according to the FDA. The agency advises anyone who suspects that they have developed symptoms resembling a listeriosis infection to contact their healthcare provider immediately.


The Onion
3 hours ago
- The Onion
FDA Recalls 3 Oranges To Prove They Can Juggle
SILVER SPRING, MD—Issuing a public warning for Americans to watch or they might miss out, the U.S. Food and Drug Administration reportedly recalled three navel oranges Wednesday to prove that they could juggle. 'Toss 'em here,' said spokesperson John Lavietes, adding that American consumers who had recently purchased navel, Valencia, or blood oranges should not consume the citrus fruits but instead bring three of them to the nearest FDA office so the federal agency could show them something. 'It's been a while, but we can definitely do it. Organic, GMO, even a mandarin or tangelo should be brought to this lectern immediately. Come on, any region or distributor works. They have to be firm, though. If they're not firm, we can't do it.' At press time, the FDA had recalled one more orange to replace the one that had rolled under the table.